Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) announced the publication of its first four Patent Cooperation Treaty (PCT) applications for novel tryptamine molecules aimed at treating psychiatric and neurological disorders. These applications, published by the World Intellectual Property Organization (WIPO), protect Enveric’s innovative drug candidates, positioning the company as a leader in the development of psychedelic-inspired therapies. Tryptamines, including well-known psychedelics, are under research for their potential therapeutic advantages in various mental health conditions.
Enveric Biosciences (NASDAQ: ENVB) announced CEO Dr. Joseph Tucker's participation in three investor conferences in March 2022. The events include the Q1 Virtual Investor Summit on March 8 at 11:45 a.m. ET, Citi's Psychedelic Drug Call Series on March 10 at 10:00 a.m. ET, and the Maxim 2022 Virtual Growth Conference from March 28-30. Attendees can register online for each conference. Enveric focuses on developing psychedelic-inspired mental health medicines to aid patients suffering from conditions like cancer-related distress and PTSD.
Enveric Biosciences (NASDAQ: ENVB) has filed its 10th Patent Cooperation Treaty (PCT) application focused on tryptamine-based derivative molecules, enhancing its intellectual property portfolio related to psychedelic-inspired mental health treatments. These novel compounds are linked to substances like DMT and psilocybin, which are being researched for various psychiatric disorders. Enveric aims to improve the commercial and regulatory prospects of these compounds and plans to explore out-licensing collaborations with other drug developers to maximize therapeutic potential.
Enveric Biosciences (NASDAQ: ENVB) is collaborating with the University of Calgary's Hotchkiss Brain Institute to launch a clinical trial for EVM-101, aimed at treating Cancer Related Distress (CRD). Approximately 50% of cancer patients experience significant psychological distress, highlighting a pressing medical need for effective treatments. The trial will assess the efficacy of a psilocybin-based therapy on CRD symptoms, with patient enrollment expected to begin in late 2022 or early 2023. Enveric is focused on developing innovative psychedelic-inspired mental health medications.
Enveric Biosciences (NASDAQ: ENVB) has closed its underwritten public offering, raising approximately $10 million through the sale of 20,000,000 shares of common stock and warrants. After costs, the company received net proceeds of about $9.2 million. The funds will be allocated for working capital and general corporate purposes. The offering included a 45-day option for the underwriter to purchase an additional 3,000,000 shares and/or warrants. This public offering was conducted under an effective shelf registration statement with the SEC.
Enveric Biosciences (NASDAQ: ENVB) has priced its underwritten public offering of 20 million shares of common stock, paired with warrants for an additional 20 million shares, at a combined price of $0.50 per share. The offering is expected to close by February 15, 2022, aiming to raise gross proceeds of approximately $10 million for general corporate purposes. A.G.P./Alliance Global Partners is the sole book-running manager for this offering, which includes a 45-day option for the underwriter to purchase an additional 3 million shares.
Enveric Biosciences announced the development of EV104a and EV104b, new molecular conjugates aimed at treating Osteoarthritis (OA) and other pain conditions. These conjugates combine cannabidiol (CBD) with celecoxib to improve pharmacokinetics and efficacy while reducing side effects. Pre-clinical testing is ongoing, and a provisional patent has been filed. CEO Joseph Tucker emphasized the need for better OA treatments, as current therapies are inadequate. This initiative positions Enveric to potentially enhance treatment options for patients suffering from OA-related pain.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on mental health and oncology treatments, announced that CEO Dr. Joseph Tucker will participate in two upcoming investor conferences. The first is Citi's Psychedelic Drug Call Series on February 8, 2022, at 10:00 a.m. ET, followed by the Aegis Capital Corp. Virtual Conference on February 25, 2022, at 3:00 p.m. ET. Enveric specializes in leveraging psychedelic-derived molecules and synthetic cannabinoids for innovative therapeutic solutions targeting conditions like cancer-related distress and PTSD.
Enveric Biosciences (NASDAQ: ENVB) released a shareholder letter reflecting on 2021 and outlining plans for 2022. The company raised $25 million and acquired MagicMed Industries. In 2021, they filed 15 patent applications and established a drug discovery platform. Looking forward, Enveric aims to progress its drug development pipeline, focusing on a Phase II clinical trial for Cancer Related Distress using EVM-101 and continuing to develop product candidates through AI-driven discovery. As of September 30, 2021, Enveric had $21 million in cash, supporting their business strategy.
Enveric Biosciences (NASDAQ: ENVB) has announced that CEO Dr. Joseph Tucker will participate in the H.C. Wainwright BioConnect Conference scheduled for January 10-13, 2022. His corporate presentation will be available on-demand starting January 10. The company focuses on developing innovative mental health and oncology treatments using psychedelic-derived molecules and synthetic cannabinoids. Enveric aims to address conditions like cancer-related distress and PTSD, supporting drug development for millions of patients worldwide.